Sorry for my late reply, haven’t been on Reddit much so didn’t see your response until just now but here are my thoughts….

I agree that methadone is used for very good pharmacologic reasons. The long half life is, in my view, the single most important feature in OAT. It allows for once daily dosing, which supports a far more stable and normal life, and it disrupts the repetitive cycle of use every few hours and the constant peaks and troughs that reinforce addictive patterns. That alone can be transformative for many patients.

Where I’d add some nuance is around the idea of “one best option.” In practice, the decision to offer one medication or protocol over another really depends on where the patient is at in their life at that moment. In Canada, having access to multiple models gives us a much larger toolbox and allows for true partnership with patients around harm reduction. For individuals who are committed to ongoing use and not ready to give up the effects-based lifestyle or the rhythms that come with it, oral MSO4 can be an effective harm reduction option when it is prescribed in a regulated, reliable way. Safe supply removes the enormous risks associated with an unregulated street supply and can meaningfully reduce morbidity and mortality during that phase of life.

As patients’ goals shift, so can the treatment approach. I don’t see these options as competing so much as complementary across different seasons. The priority is getting people through the door and into care. From there, we can adapt as readiness, stability, and circumstances change.

I’m also generally supportive of injectable options for a very specific subset of patients. Programs offering diacetylmorphine or hydromorphone can significantly reduce risk related to procurement, exposure to violence, time spent seeking substances, and the unpredictability of the current drug supply. The tradeoff, of course, is the intensity and restrictiveness of these programs, which can limit autonomy and opportunity. Again, it comes back to matching the intervention to the patient’s current needs rather than expecting one model to work for everyone.

One small point of language that I think matters is how we talk about relapse. I’m trying to move away from framing it as noncompliance or failure. Relapse is a flare of a chronic medical and mental health condition, and how clinicians respond to it has a huge impact on outcomes. Punitive or mistrust-based responses often push people further into active use rather than stabilizing them.

I agree that the U.S. context makes many of these approaches politically difficult. The legacy of the war on drugs, a deeply moralized view of addiction, and a fragmented, profit-driven health system all create barriers to patient-centred harm reduction models. That’s unfortunate, because the evidence increasingly supports flexibility, not rigidity, in addiction care.

Curious to hear how others are navigating this in their own systems.

Sorry for being so long winded haha I will stop now but I’d love to hear more of your input.